Promising Therapy for Patients with Advanced Kidney Cancer Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations. The superior ...
Bristol-Myers Squibb Company announced topline results from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and ...
Real-world data gathered from the U.S. Oncology Network suggested that outcomes with first-line nivolumab plus ipilimumab (1L NIVO+IPI) in patients with metastatic renal cell carcinoma (mRCC) are ...
Bristol-Myers Squibb Company announced patient-reported outcomes data from the phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma (RCC) treated ...
Bristol-Myers Squibb Company BMY announced disappointing top-line results from the CheckMate-214 trial. The study investigated immuno-oncology drug Opdivo (nivolumab) in combination with Yervoy ...
Bristol-Myers Squibb CompanyBMY announced encouraging data from the phase III CheckMate -214 study on Opdivo. CheckMate-214 study is an ongoing study evaluating Immuno-Oncology combination Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback